Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CSF shunts cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (47 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 558 | 46% |
| 2020 | 3 | 384 | 48% |
| 2021 | 5 | 499 | 51% |
Ventriculoperitoneal shunt placement and revision, including normal-pressure hydrocephalus. Professional codes (what the surgeon bills): CPT 62223, 62230.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New York; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 2 | 238−9.5%/yr | −9.5%/yr | 0.2 | 0% | 280 in 2030+2.8%/yr |
| Massachusetts | 5 | 193 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Aneurysm & intracranial embolization | 25 | 1,148+12%/yr | +12%/yr | 0.61.3× | 0% | 1,980 in 2030+9.5%/yr |
| Stroke thrombectomy |
CSF shunts in every state, and its device makers · Every procedure market in New York · Every state · Compare with Pennsylvania
| 2024 |
| 455 |
| 57% |
| 2025 est. | ≈ 570 | – |
| 2026 est. | ≈ 580 | – |
| 2022 | 4 | 497 | 53% |
| 2023 | 8 | 490 | 55% |
| 2024 | 6 | 455 | 57% |
| 2025 from claims | – | 568 459–667 | 58% |
| 2026 forecast | – | 576 451–724 | 58% |
| 2027 forecast | – | 583 432–770 | 59% |
| 2028 forecast | – | 589 417–813 | 59% |
| 2029 forecast | – | 595 405–853 | 60% |
| 2030 forecast | – | 601 394–893 | 60% |
In 2025, 92% inpatient hospital, 8% hospital outpatient.
| −8.4%/yr |
| 0.2 |
| 0% |
| 220 in 2030+1.9%/yr |
| New Jersey | 0 | 134−11%/yr | −11%/yr | 0.1 | 0% | 120 in 2030−1.3%/yr |
| Connecticut | 1 | 129+5.9%/yr | +5.9%/yr | 0.4 | 0% | 250 in 2030+12%/yr |
| 16 |
| 669+0.8%/yr |
| +0.8%/yr |
| 0.40.8× |
| 0% |
| 800 in 2030+3%/yr |
| DBS & VNS | 8 | 452−3.8%/yr | −3.8%/yr | 0.20.9× | 0% | 480 in 2030+0.9%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
New York’s own discharge file counts every inpatient stay, whatever the payer: 1,119 csf shunts stays at 23 hospitals in 2024, against the Medicare-only figures above. The most commercial of the busy ones is MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (52% commercial): where commercial rates leave the most room for a premium product.
| Hospital | Cases | Medicare | Commercial |
|---|---|---|---|
| NYU LANGONE HOSPITALS NEW YORK | 153 | 61% | 21% |
| NEW YORK-PRESBYTERIAN HOSPITAL NEW YORK | 131 | 44% | 36% |
| KALEIDA HEALTH BUFFALO | 113 | 65% | 17% |
| MOUNT SINAI HOSPITAL NEW YORK | 97 | 65% | 21% |
| ALBANY MEDICAL CENTER HOSPITAL ALBANY | 76 | 36% | — |
| MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES NEW YORK | 64 | — | 52% |
| NORTH SHORE UNIVERSITY HOSPITAL MANHASSET | 54 | 67% | — |
| UNIVERSITY HOSPITAL S U N Y HEALTH SCIENCE CENTER SYRACUSE | 45 | 51% | — |
New York only: MedaRep has no other state’s all-payer file yet. Counted by principal procedure (CSF shunts). Medicare here includes Medicare Advantage. A hospital with 10 or fewer such stays, or a payer share of 10 or fewer, is not shown. Source: New York State Department of Health, SPARCS de-identified inpatient discharges (health.data.ny.gov). The New York State Department of Health makes no representation, warranty or guarantee relating to the data or analyses derived from these data. Accessed 2026-11-11.
Johnson & Johnson MedTech leads with 78% of company spending on these surgeons in 2025, −9 pts on 2024.
In 2025, 6 companies reported engagement with New York’s surgeons worth $254K in consulting, speaking, meals and travel tied to these products, about $42K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.